Navigation Links
Genesis Biopharma Appoints William H. Andrews Ph.D. to Board of Directors
Date:3/17/2011

LOS ANGELES, March 17, 2011 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC Bulletin Board: GNBP), a biotechnology company developing targeted cancer therapies, today announced it has appointed William H. Andrews Ph.D. to its Board of Directors.  Dr. Andrews has three decades experience in biotechnology research and development, and is currently President and Chief Executive Officer of Sierra Sciences, LLC, a company he founded in 1999.

"Dr. Andrews brings a wealth of scientific expertise and professional experience to Genesis Biopharma," said Anthony J. Cataldo, President and Chief Executive Officer. "His background in the clinical and regulatory development of drug candidates, as well as in building a successful business, makes him an excellent fit with the Company's new leadership team.  In the last few weeks we have made significant progress in building Genesis Biopharma's Board and senior management, and I believe we are well-positioned to grow the Company through further development of our monoclonal antibody technology, leveraging our research collaborations, and exploring new strategic opportunities."

Prior to founding Sierra Sciences, Dr. Andrews was director of technology development for EOS Biotechnology.  Previously he served as director of molecular biology at both Geron Corporation and Codon Corporation.  While at Geron from 1992 to 1997, Dr. Andrews was one of the principal discoverers of both the RNA and protein components of human telomerase and was awarded 2nd place as "National Inventor of the Year" by the Intellectual Property Owners Association in 1997 for this work. He is presently a named inventor on 43 U.S. issued telomerase patents.  He received his doctorate in Molecular and Population Genetics from the University of Georgia.

Last month the Company announced the appointment of Dr. L. Stephen Coles to the Board in addition to the earlier Board appointments of Mr. Cataldo and Chief Financial Officer Michael Handelman.  The Genesis Biopharma Board now consists of 4 members, including 2 independent Directors.  Also, the Company announced last week that it had named Marvin S. Hausman M.D. as Chief Science Officer.

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is a development-stage biotechnology company engaged in the development of targeted cancer therapies.  For more information about the company, visit www.genesis-biopharma.com.

Forward-Looking Statements

The foregoing press announcement contains forward-looking statements that can be identified by such terminology as "expect," "potential," "suggests," "bodes," "may," "should," "could" or similar expressions.  Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements.  In particular, management's expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the company's ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as of the date they are made. The company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.


'/>"/>
SOURCE Genesis Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Genesis Biopharma Announces Plans to Develop Active Immunotherapy Platform
2. Genesis Biopharma Appoints L. Stephen Coles M.D., Ph.D. to Board of Directors
3. Genesis Biopharma to Present at the Lippert/Heilshorn Life Sciences and Medtech Virtual Conference on February 17
4. Genesis Biopharma Announces Management and Board Changes
5. Waters Releases NuGenesis SDMS 7.1 Validated to Support Windows 7 and Empower 3 CDS
6. Genesis Biopharma Expresses Support for FDA Codevelopment Guidelines
7. Genesis Biopharma Raises $845,000 in Private Financings
8. Genesis Biopharma to Present at the Informed Investors Forum Biotech, Healthcare & Pharma Virtual Conference on October 13
9. Genesis Biopharma Announces $700K Private Financing
10. ThermoGenesis Announces Sale of BioArchive Systems In Asia as Company Increases Presence In Key Market
11. American Medical Systems and Tissue Genesis Sign $1.1 Million Collaboration Deal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... 2017 , ... LabRoots , the leading provider of educational and interactive ... to announce the launch of a new scholarship for young scientists seeking a degree ... scholarship is open to all high school seniors, 17 years or older; as well ...
(Date:2/22/2017)... Zurich, Switzerland (PRWEB) , ... February 22, 2017 ... ... Ltd ., announced the addition of Tom Perkins as European director. Operating from ... consulting experience to Pennside. , Perkins joins Pennside after more than a ...
(Date:2/21/2017)... ... February 21, 2017 , ... During HIMSS 2017, CloudMine, a ... announced a partnership with Redox, a leader in cloud-based healthcare integration and API ... while keeping data secure in the cloud. , The digital health developers, and ...
(Date:2/21/2017)... (PRWEB) , ... February 21, ... ... the Life -Sciences division, Treximo will pair its $200M operational capacity with ... consulting and project management in areas affecting quality and operational management. ...
Breaking Biology Technology:
(Date:1/30/2017)... , Jan. 30, 2017   Invitae Corporation ... fastest growing genetic information companies, today announced that it ... results and provide 2017 guidance on Monday, February 13, ... call that day at 4:45 p.m. Eastern / 1:45 ... management team will briefly review financial results, guidance, and ...
(Date:1/24/2017)... PHILADELPHIA , Jan. 24, 2017  It ... a baby,s sock that monitors vital signs and ... instance, an infant,s oxygen saturation level drops. But ... undue alarm to parents, with no evidence of ... "These devices are marketed aggressively to parents of ...
(Date:1/18/2017)... 18, 2017  In vitro diagnostic (IVD) companies were ... acquisitions (M&A), and Kalorama Information expects that trend to ... been shifting. Generally, uncertainty in reimbursement and healthcare reform ... has changed the acquisitions landscape. Instead of looking to ... buying partners outside of their home country and also ...
Breaking Biology News(10 mins):